or Try an Advanced Search...

    Advanced Solid Tumors Stocks List

    Symbol Grade Name % Change
    ADCT C ADC Therapeutics SA 0.00
    CASI F CASI Pharmaceuticals, Inc. 0.00
    CRDF D Cardiff Oncology, Inc. 0.00
    CLRB D Cellectar Biosciences, Inc. 0.00
    ELEV D Elevation Oncology, Inc. 0.00
    IMRX F Immuneering Corporation 0.00
    PPBT F Purple Biotech Ltd. 0.00
    RLAY F Relay Therapeutics, Inc. 0.00
    SLRX F Salarius Pharmaceuticals, Inc. 0.00
    STTK B Shattuck Labs, Inc. 0.00
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research
    Related Stock Lists: Solid Tumors Cancer Clinical Medicine Medicine Biotechnology Oncology Antineoplastic Drugs Cancer Treatment Life Sciences Ovarian Cancer Treatment Of Cancer Autoimmune Disease Biopharmaceutical Chemotherapy Drugs Leukemia Lymphoma Pharmaceutical Prostate Cancer Targeted Therapy

    Related ETFs - A few ETFs which own one or more of the above listed Advanced Solid Tumors stocks.

    Symbol Grade Name Weight
    CNCR D Loncar Cancer Immunotherapy ETF 1.76
    LRNZ D TrueMark Technology, AI & Deep Learning ETF 0.92
    BBC D Virtus LifeSci Biotech Clinical Trials ETF 0.54
    XBI D SPDR S&P Biotech ETF 0.37
    BTEC C Principal Healthcare Innovators Index ETF 0.22
    View all Advanced Solid Tumors ETFs...
    Compare ETFs
    Compare BBC to XBI Compare CNCR to BBC Compare CNCR to XBI

        Advanced Solid Tumors Stocks Recent News

        Date Stock Title
        May 4 RLAY Relay Therapeutics First Quarter 2024 Earnings: Beats Expectations
        May 4 CRDF Cardiff Oncology First Quarter 2024 Earnings: Beats Expectations
        May 4 STTK Shattuck Labs First Quarter 2024 Earnings: Beats Expectations
        May 4 STTK Shattuck Labs Inc (STTK) Reports First Quarter 2024 Financial Results
        May 3 ELEV Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling
        May 3 RLAY Relay Therapeutics GAAP EPS of -$0.62 beats by $0.10, revenue of $10.01M beats by $9.09M
        May 3 CRDF Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript
        May 2 RLAY Relay Therapeutics Outperforms Revenue Expectations in Q1 2024
        May 2 RLAY Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates
        May 2 RLAY Relay Therapeutics GAAP EPS of -$0.62 beats by $0.08, revenue of $10M beats by $9.89M
        May 2 CRDF Cardiff Oncology GAAP EPS of -$0.22 beats by $0.03, revenue of $0.2M beats by $0.14M
        May 2 RLAY Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
        May 2 CRDF Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
        May 2 ELEV Elevation Oncology files for $350M mixed shelf
        May 2 STTK Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates
        May 2 ELEV Elevation Oncology GAAP EPS of -$0.23
        May 2 STTK Shattuck Labs GAAP EPS of -$0.37, revenue of $1.11M
        May 2 ELEV Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
        May 2 STTK Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
        May 1 CRDF Cardiff Oncology Q1 2024 Earnings Preview
        Related Industries: Biotechnology Diagnostics & Research
        Related Stock Lists: Breast Cancer Cancer Clinical Development Medicine Oncology Ovarian Cancer Prostate Cancer Sarcoma Solid Tumors Treatment Of Breast Cancer
        Advanced Solid Tumors

        Advanced solid tumors are cancerous tumors that have spread beyond the original site of the tumor and have become more difficult to treat. These tumors are often referred to as metastatic or stage IV tumors. Advanced solid tumors can affect any part of the body and can be caused by a variety of different types of cancer. Treatment options for advanced solid tumors may include surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, and/or clinical trials.

        Browse All Tags